# US 2012/0252812 A1 · 6-pyrimidinyl-pyrimid-4-one derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252812 A1
- Document ID: US20120252812A1
- Status: Published application
- Kind: A1
- Application number: 13/467,302
- Filed: 2012-05-09
- Published: 2012-10-04
- Earliest claimed: 2007-09-14
- Assignees: Sanofi-Aventis; Mitsubishi Tanabe Pharma Corporation
- Inventors: Kenji FUKUNAGA; Kazutoshi WATANABE; Pascal BARNEOUD; Jesus BENAVIDES; Jeremy PRATT
- Web page: https://patentgrep.com/patent/US20120252812A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/14: for baldness or alopecia
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

## Claims

### Claim 1

A method of treating a neurodegenerative disease comprising administering a compound represented by formula (I)
or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the disease is selected from the group consisting of Alzheimer's disease, ischemic cerebrovascular accidents, progressive supranuclear palsy, Pick's disease, corticobasal degeneration, frontotemporal dementia, traumatic injuries, and brain and spinal cord trauma.

### Claim 3

A method of treating non-insulin dependent diabetes comprising administering a compound represented by formula (I)
or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.

### Claim 4

A method of treating a disease characterized by cognitive and memory deficits comprising administering a compound represented by formula (I)
or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
